

August 19, 2014
Daiwa PI Partners Co. Ltd.

Daiwa PI Partners to Invest in Original BioMedicals Co., Ltd. in Taiwan.

Daiwa PI Partners Co. Ltd. (President: Hideki Araki, Headquarter: Gran Tokyo North Tower 1-9-1, Marunouchi, Chiyoda-ku, Tokyo), a wholly consolidated subsidiary of Daiwa Securities Group Inc., subscribed newly issued ordinary shares of Original BioMedicals Co., Ltd. (Chairman: Duncan Chen, Headquarter: 2F, No. 6, Sec. 1, HuanDong Rd., XinShi Dist., Tainan City 74147, Taiwan/"OBM") with a subscribed amount NTD135 million of total issued amount NTD270 million.

OBM, a privately held biotechnology company, has successfully invented an original drug delivery system ("DDS"), which can improve effectiveness and convenience of existing drugs approved by the United States Food & Drug Administration ("FDA"). With its original DDS, OBM develops new drugs and plans to license them out to pharmaceutical organizations and biotechnology companies while discovering new pipelines. OBM will utilize the proceeds from this transaction for research and development, patent application, and others.

1. Summary of new ordinary shares subscription

Issuer	Original BioMedicals Co., Ltd.
Subscriber	Daiwa PI Partners Co. Ltd.
Amount subscribed	Subscribed NTD135 million of total issued amount NTD270 million
Payment date	August 19, 2014

2. Summary of OBM

Establishment date	December 5, 2011
Address	2F, No. 6, Sec. 1, HuanDong Rd., XinShi Dist., Tainan City 74147, Taiwan
Number of employees	15
Business description	Develops new drugs using its own DDS named CCM (Chelating Complex Micelles).
Website URL	http://www.i-obm.com/index-lang2.html